Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Pituitary Disorders
Should we be considering transsphenoidal surgical resection as first-line therapy for prolactinomas?
Wu, PMID 38253861
Answer from: at Community Practice
A dopamine agonist is the first line of treatment for prolactinomas because most patients respond well to this treatment and tolerate it.
Sign in or Register to read more
25433
Related Questions
Should we be aiming for normalization of both late-night salivary cortisol and 24hr urinary free cortisol levels when monitoring response to Cushing's disease treatment?
Do you recommend increased screening for hypercortisolism in older patients given recent evidence that older patients do not commonly display hallmark symptoms of Cushing's Disease?
Does hyperprolactinemia always need to be treated if the patient has regular menses, no galactorrhea, no desire for fertility and MRI of the pituitary is normal?
How would you manage new onset amenorrhea, diabetes insipidus and growth hormone deficiency without other pituitary deficiencies or excess in young females with MRI findings of pituitary mass and hypothalamic edema?
In patients with confirmed hypercortisolism with a high/normal unsuppressed ACTH who have both a pituitary adenoma and adrenal adenoma identified on imaging, can you reliably use DHEA-S to determine the source of cortisol production?
How do you evaluate remission in acromegaly when postoperative IGF-1 and GH levels are discordant?
What degree of prolactin elevation is typically seen in patients with end stage kidney disease on hemodialysis?
How do you approach mild prolactin elevations (20-80) in women with galactorrhea on nipple stimulation but regular menses and no plans for pregnancy?
What are the advantages of oral octreotide acetate over its long acting injectable formulation for treatment of acromegaly?
Do you pursue additional cardiac evaluation for patients diagnosed with Sheehan Syndrome, considering their elevated risk for atherosclerotic cardiovascular diseases?